Follow Health Care Reform Insider on Twitter
You are here:  Home  >  Public Health  >  Current Article

FDA shouldn’t fall for latest ruse to derail biosimilars competition

September 19, 2014 

Headlines about the rising cost of healthcare in the United States are a dime a dozen these days. But imagine how much worse off we would be without low-cost generic drugs, which save consumers $3 billion a week.  That’s exactly the overpriced nightmare we could face if the Food and Drug Administration (FDA) does not take the right approach in regulating the latest advanced pharmaceutical therapies.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>